<?xml version="1.0" encoding="UTF-8"?>
<p>Replication-defective recombinant adenoviruses (rAd) have been developed as vectors for gene therapy or vaccines against human immunodeficiency virus (HIV), hepatitis virus, influenza virus, and certain types of cancers [
 <xref rid="B8-viruses-09-00234" ref-type="bibr">8</xref>,
 <xref rid="B12-viruses-09-00234" ref-type="bibr">12</xref>,
 <xref rid="B13-viruses-09-00234" ref-type="bibr">13</xref>,
 <xref rid="B14-viruses-09-00234" ref-type="bibr">14</xref>,
 <xref rid="B15-viruses-09-00234" ref-type="bibr">15</xref>,
 <xref rid="B16-viruses-09-00234" ref-type="bibr">16</xref>,
 <xref rid="B17-viruses-09-00234" ref-type="bibr">17</xref>,
 <xref rid="B18-viruses-09-00234" ref-type="bibr">18</xref>]. Adenovirus-vectored influenza vaccines have been reported to be safe [
 <xref rid="B19-viruses-09-00234" ref-type="bibr">19</xref>,
 <xref rid="B20-viruses-09-00234" ref-type="bibr">20</xref>,
 <xref rid="B21-viruses-09-00234" ref-type="bibr">21</xref>], and have also been demonstrated to confer broad protection against multiple influenza virus subtypes [
 <xref rid="B22-viruses-09-00234" ref-type="bibr">22</xref>,
 <xref rid="B23-viruses-09-00234" ref-type="bibr">23</xref>,
 <xref rid="B24-viruses-09-00234" ref-type="bibr">24</xref>,
 <xref rid="B25-viruses-09-00234" ref-type="bibr">25</xref>,
 <xref rid="B26-viruses-09-00234" ref-type="bibr">26</xref>,
 <xref rid="B27-viruses-09-00234" ref-type="bibr">27</xref>].
</p>
